RGNX – REGENXBIO Inc.
Float Short %
10.9
Margin Of Safety %
Put/Call OI Ratio
0.43
EPS Next Q Diff
-0.19
EPS Last/This Y
1.33
EPS This/Next Y
1.21
Price
15.98
Target Price
32.67
Analyst Recom
1.42
Performance Q
22.08
Relative Volume
1.23
Beta
1.05
Ticker: RGNX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | RGNX | 14.18 | 0.71 | 0.74 | 4858 |
| 2025-12-29 | RGNX | 14.31 | 0.72 | 0.35 | 4878 |
| 2025-12-30 | RGNX | 14.1 | 0.72 | 0.07 | 4889 |
| 2025-12-31 | RGNX | 14.41 | 0.74 | 0.00 | 4987 |
| 2026-01-02 | RGNX | 13.57 | 0.74 | 1.50 | 5001 |
| 2026-01-05 | RGNX | 13.39 | 0.78 | 0.13 | 5223 |
| 2026-01-06 | RGNX | 14.17 | 0.75 | 0.00 | 5367 |
| 2026-01-07 | RGNX | 15.25 | 0.74 | 0.02 | 5390 |
| 2026-01-08 | RGNX | 15.03 | 0.73 | 0.48 | 5441 |
| 2026-01-09 | RGNX | 14.56 | 0.73 | 0.20 | 5575 |
| 2026-01-12 | RGNX | 15.07 | 0.72 | 0.71 | 5655 |
| 2026-01-13 | RGNX | 15.06 | 0.72 | 0.03 | 5889 |
| 2026-01-14 | RGNX | 14.95 | 0.69 | 0.11 | 6013 |
| 2026-01-15 | RGNX | 13.75 | 0.70 | 0.37 | 6033 |
| 2026-01-16 | RGNX | 13.64 | 0.70 | 0.17 | 7673 |
| 2026-01-20 | RGNX | 14.13 | 0.39 | 0.50 | 4523 |
| 2026-01-21 | RGNX | 15 | 0.41 | 0.19 | 5121 |
| 2026-01-22 | RGNX | 15.96 | 0.43 | 0.46 | 5284 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | RGNX | 14.18 | 21.0 | 239.6 | -3.26 |
| 2025-12-29 | RGNX | 14.27 | 21.0 | 243.4 | -3.26 |
| 2025-12-30 | RGNX | 14.10 | 21.0 | 240.2 | -3.26 |
| 2025-12-31 | RGNX | 14.40 | 21.0 | 245.5 | -3.26 |
| 2026-01-02 | RGNX | 13.57 | 21.0 | 233.8 | -3.26 |
| 2026-01-05 | RGNX | 13.40 | 21.0 | 240.3 | -3.26 |
| 2026-01-06 | RGNX | 14.16 | 21.0 | 250.8 | -3.26 |
| 2026-01-07 | RGNX | 15.24 | 21.0 | 253.2 | -3.26 |
| 2026-01-08 | RGNX | 14.98 | 21.0 | 239.8 | -3.26 |
| 2026-01-09 | RGNX | 14.57 | 22.6 | 238.2 | -3.26 |
| 2026-01-12 | RGNX | 15.10 | 22.6 | 247.3 | -3.26 |
| 2026-01-13 | RGNX | 15.03 | 22.6 | 241.8 | -3.26 |
| 2026-01-14 | RGNX | 14.94 | 22.6 | 241.2 | -3.26 |
| 2026-01-15 | RGNX | 13.76 | 22.6 | 230.8 | -3.26 |
| 2026-01-16 | RGNX | 13.64 | 22.6 | 241.0 | -3.26 |
| 2026-01-20 | RGNX | 14.11 | 22.6 | 247.7 | -3.26 |
| 2026-01-21 | RGNX | 15.00 | 22.6 | 251.4 | -3.26 |
| 2026-01-22 | RGNX | 15.98 | 22.6 | 251.5 | -3.26 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | RGNX | -0.80 | -1.21 | 11.07 |
| 2025-12-29 | RGNX | -0.80 | -1.21 | 11.07 |
| 2025-12-30 | RGNX | -0.80 | -1.21 | 11.07 |
| 2025-12-31 | RGNX | -0.80 | -1.21 | 11.07 |
| 2026-01-02 | RGNX | -0.80 | -1.21 | 11.07 |
| 2026-01-05 | RGNX | -0.80 | -1.21 | 11.07 |
| 2026-01-06 | RGNX | -0.80 | -1.21 | 11.07 |
| 2026-01-07 | RGNX | -0.80 | -1.21 | 11.07 |
| 2026-01-08 | RGNX | -0.80 | -1.21 | 11.07 |
| 2026-01-09 | RGNX | -0.80 | -1.21 | 11.07 |
| 2026-01-12 | RGNX | -0.78 | -1.14 | 11.21 |
| 2026-01-13 | RGNX | -0.71 | -1.14 | 10.90 |
| 2026-01-14 | RGNX | -0.71 | -1.14 | 10.90 |
| 2026-01-15 | RGNX | -0.71 | -1.14 | 10.90 |
| 2026-01-16 | RGNX | -0.71 | -1.14 | 10.90 |
| 2026-01-20 | RGNX | -0.71 | -0.65 | 10.90 |
| 2026-01-21 | RGNX | -0.71 | -0.65 | 10.90 |
| 2026-01-22 | RGNX | -0.71 | -0.65 | 10.90 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.2
Avg. EPS Est. Current Quarter
-0.8
Avg. EPS Est. Next Quarter
-1.39
Insider Transactions
-0.71
Institutional Transactions
-0.65
Beta
1.05
Average Sales Estimate Current Quarter
61
Average Sales Estimate Next Quarter
68
Fair Value
Quality Score
39
Growth Score
45
Sentiment Score
35
Actual DrawDown %
67.7
Max Drawdown 5-Year %
-89.1
Target Price
32.67
P/E
Forward P/E
PEG
P/S
5.01
P/B
5.01
P/Free Cash Flow
EPS
-3.49
Average EPS Est. Cur. Y
-3.26
EPS Next Y. (Est.)
-2.05
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-110.29
Relative Volume
1.23
Return on Equity vs Sector %
-137.4
Return on Equity vs Industry %
-121.5
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.06
EBIT Estimation
251.5
REGENXBIO Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 353
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
stock quote shares RGNX – REGENXBIO Inc. Stock Price stock today
news today RGNX – REGENXBIO Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RGNX – REGENXBIO Inc. yahoo finance google finance
stock history RGNX – REGENXBIO Inc. invest stock market
stock prices RGNX premarket after hours
ticker RGNX fair value insiders trading